A068270 Stock Overview
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celltrion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩178,700.00 |
| 52 Week High | ₩241,000.00 |
| 52 Week Low | ₩131,000.00 |
| Beta | 0.33 |
| 1 Month Change | -5.05% |
| 3 Month Change | -1.60% |
| 1 Year Change | 7.33% |
| 3 Year Change | -33.49% |
| 5 Year Change | -6.01% |
| Change since IPO | 1,698.22% |
Recent News & Updates
Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues
Mar 25
We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt
Mar 19Recent updates
Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues
Mar 25We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt
Mar 19Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock
May 05Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)
Mar 25Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like
Mar 15Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?
Feb 24Celltrion (KRX:068270) Has A Rock Solid Balance Sheet
Feb 03Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?
Jan 13
Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?
Dec 23Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?
Dec 02Shareholder Returns
| A068270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.06% | -4.0% | -3.3% |
| 1Y | 7.3% | 0.7% | 1.2% |
Return vs Industry: A068270 exceeded the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A068270 exceeded the KR Market which returned 1.2% over the past year.
Price Volatility
| A068270 volatility | |
|---|---|
| A068270 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A068270 has not had significant price volatility in the past 3 months.
Volatility Over Time: A068270's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Hyong-Gi Kim | www.celltrion.com |
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial.
Celltrion, Inc. Fundamentals Summary
| A068270 fundamental statistics | |
|---|---|
| Market cap | ₩37.04t |
| Earnings (TTM) | ₩535.65b |
| Revenue (TTM) | ₩2.18t |
69.2x
P/E Ratio17.0x
P/S RatioIs A068270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A068270 income statement (TTM) | |
|---|---|
| Revenue | ₩2.18t |
| Cost of Revenue | ₩1.12t |
| Gross Profit | ₩1.05t |
| Other Expenses | ₩516.22b |
| Earnings | ₩535.65b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58k |
| Gross Margin | 48.33% |
| Net Profit Margin | 24.61% |
| Debt/Equity Ratio | 10.9% |
How did A068270 perform over the long term?
See historical performance and comparison